Trastuzumab and thyroid dysfunction: An association to be aware of
The incidence of autoimmune thyroid disorders is higher among women with breast cancer (BC) than in other solid malignancies, while it has not a prognostic impact. Trastuzumab (T) is a humanized monoclonal antibody approved for human epidermal growth factor receptor 2 (HER2)-positive BC in the neoad...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and therapeutics 2022-10, Vol.18 (4), p.1183-1185 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1185 |
|---|---|
| container_issue | 4 |
| container_start_page | 1183 |
| container_title | Journal of cancer research and therapeutics |
| container_volume | 18 |
| creator | Sánchez-Bayona, Rodrigo Garcia del Barrio, Maria Alegre, Estibaliz Fernandez-Hidalgo, Oscar Eslava, Marta |
| description | The incidence of autoimmune thyroid disorders is higher among women with breast cancer (BC) than in other solid malignancies, while it has not a prognostic impact. Trastuzumab (T) is a humanized monoclonal antibody approved for human epidermal growth factor receptor 2 (HER2)-positive BC in the neoadjuvant, adjuvant, and metastatic scenarios. Since 2014, subcutaneous (SC) T has been employed with the same efficacy as the intravenous formulation together with an easier way of administration. To date, autoimmune thyroiditis has been linked rarely to the use of intravenous T, and no cases have been related to the SC presentation. We report two cases of HER2-positive early BC patients who developed hypothyroidism during maintenance therapy with SC T that required levothyroxine supplementation. SC T includes recombinant human hyaluronidase to facilitate tissue penetration of the drug. This enzyme may alter the thyroid gland stroma and facilitate the development of thyroid disorders. Thyroid function tests are recommended in patients on SC T. |
| doi_str_mv | 10.4103/jcrt.JCRT_66_19 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2718075140</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A719770716</galeid><sourcerecordid>A719770716</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433u-b03274f7836628feee473d0b82a16af3b6be9746401c80816919940eed5703b43</originalsourceid><addsrcrecordid>eNp1kU1LAzEQhoMoWKtnrwHPW5NNmmS91eIngiD1HLLZiW7dTTTZpdRf75YqIlRyGDI8z8zAi9ApJRNOCTtf2thN7udPCy2EpsUeGtGiUBmnTO2jESkkyyhX-SE6SmlJyFTmuRqhy0U0qes_-9aU2PgKd6_rGOoKV-vkem-7OvgLPPPYpBRsbTZ_3AVcAjYrEwEHd4wOnGkSnHzXMXq-vlrMb7OHx5u7-ewhs5yxPisJyyV3UjEhcuUAgEtWkVLlhgrjWClKKCQXnFCriKKiGO7nBKCaSsJKzsbobDv3PYaPHlKnl6GPflipc0kVkVPKyS_1YhrQtXehi8a2dbJ6JmkhJZFUDFS2g3oBD9E0wYOrh_YffrKDH14FbW13CudbwcaQUgSn32PdmrjWlOhNXnqTl_7NazAut8YqNB3E9Nb0K4i6herNh9V_mqZUMf0TIvsCvRGeQg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2718075140</pqid></control><display><type>article</type><title>Trastuzumab and thyroid dysfunction: An association to be aware of</title><source>Medknow Open Access Medical Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Sánchez-Bayona, Rodrigo ; Garcia del Barrio, Maria ; Alegre, Estibaliz ; Fernandez-Hidalgo, Oscar ; Eslava, Marta</creator><creatorcontrib>Sánchez-Bayona, Rodrigo ; Garcia del Barrio, Maria ; Alegre, Estibaliz ; Fernandez-Hidalgo, Oscar ; Eslava, Marta</creatorcontrib><description>The incidence of autoimmune thyroid disorders is higher among women with breast cancer (BC) than in other solid malignancies, while it has not a prognostic impact. Trastuzumab (T) is a humanized monoclonal antibody approved for human epidermal growth factor receptor 2 (HER2)-positive BC in the neoadjuvant, adjuvant, and metastatic scenarios. Since 2014, subcutaneous (SC) T has been employed with the same efficacy as the intravenous formulation together with an easier way of administration. To date, autoimmune thyroiditis has been linked rarely to the use of intravenous T, and no cases have been related to the SC presentation. We report two cases of HER2-positive early BC patients who developed hypothyroidism during maintenance therapy with SC T that required levothyroxine supplementation. SC T includes recombinant human hyaluronidase to facilitate tissue penetration of the drug. This enzyme may alter the thyroid gland stroma and facilitate the development of thyroid disorders. Thyroid function tests are recommended in patients on SC T.</description><identifier>ISSN: 0973-1482</identifier><identifier>EISSN: 1998-4138</identifier><identifier>DOI: 10.4103/jcrt.JCRT_66_19</identifier><language>eng</language><publisher>Mumbai: Wolters Kluwer India Pvt. Ltd</publisher><subject>Breast cancer ; Diagnosis ; Hypothyroidism ; Monoclonal antibodies ; Risk factors ; Targeted cancer therapy ; Thyroid gland</subject><ispartof>Journal of cancer research and therapeutics, 2022-10, Vol.18 (4), p.1183-1185</ispartof><rights>COPYRIGHT 2022 Medknow Publications and Media Pvt. Ltd.</rights><rights>2022. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433u-b03274f7836628feee473d0b82a16af3b6be9746401c80816919940eed5703b43</citedby><cites>FETCH-LOGICAL-c433u-b03274f7836628feee473d0b82a16af3b6be9746401c80816919940eed5703b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27458,27924,27925</link.rule.ids></links><search><creatorcontrib>Sánchez-Bayona, Rodrigo</creatorcontrib><creatorcontrib>Garcia del Barrio, Maria</creatorcontrib><creatorcontrib>Alegre, Estibaliz</creatorcontrib><creatorcontrib>Fernandez-Hidalgo, Oscar</creatorcontrib><creatorcontrib>Eslava, Marta</creatorcontrib><title>Trastuzumab and thyroid dysfunction: An association to be aware of</title><title>Journal of cancer research and therapeutics</title><description>The incidence of autoimmune thyroid disorders is higher among women with breast cancer (BC) than in other solid malignancies, while it has not a prognostic impact. Trastuzumab (T) is a humanized monoclonal antibody approved for human epidermal growth factor receptor 2 (HER2)-positive BC in the neoadjuvant, adjuvant, and metastatic scenarios. Since 2014, subcutaneous (SC) T has been employed with the same efficacy as the intravenous formulation together with an easier way of administration. To date, autoimmune thyroiditis has been linked rarely to the use of intravenous T, and no cases have been related to the SC presentation. We report two cases of HER2-positive early BC patients who developed hypothyroidism during maintenance therapy with SC T that required levothyroxine supplementation. SC T includes recombinant human hyaluronidase to facilitate tissue penetration of the drug. This enzyme may alter the thyroid gland stroma and facilitate the development of thyroid disorders. Thyroid function tests are recommended in patients on SC T.</description><subject>Breast cancer</subject><subject>Diagnosis</subject><subject>Hypothyroidism</subject><subject>Monoclonal antibodies</subject><subject>Risk factors</subject><subject>Targeted cancer therapy</subject><subject>Thyroid gland</subject><issn>0973-1482</issn><issn>1998-4138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kU1LAzEQhoMoWKtnrwHPW5NNmmS91eIngiD1HLLZiW7dTTTZpdRf75YqIlRyGDI8z8zAi9ApJRNOCTtf2thN7udPCy2EpsUeGtGiUBmnTO2jESkkyyhX-SE6SmlJyFTmuRqhy0U0qes_-9aU2PgKd6_rGOoKV-vkem-7OvgLPPPYpBRsbTZ_3AVcAjYrEwEHd4wOnGkSnHzXMXq-vlrMb7OHx5u7-ewhs5yxPisJyyV3UjEhcuUAgEtWkVLlhgrjWClKKCQXnFCriKKiGO7nBKCaSsJKzsbobDv3PYaPHlKnl6GPflipc0kVkVPKyS_1YhrQtXehi8a2dbJ6JmkhJZFUDFS2g3oBD9E0wYOrh_YffrKDH14FbW13CudbwcaQUgSn32PdmrjWlOhNXnqTl_7NazAut8YqNB3E9Nb0K4i6herNh9V_mqZUMf0TIvsCvRGeQg</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Sánchez-Bayona, Rodrigo</creator><creator>Garcia del Barrio, Maria</creator><creator>Alegre, Estibaliz</creator><creator>Fernandez-Hidalgo, Oscar</creator><creator>Eslava, Marta</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20221001</creationdate><title>Trastuzumab and thyroid dysfunction: An association to be aware of</title><author>Sánchez-Bayona, Rodrigo ; Garcia del Barrio, Maria ; Alegre, Estibaliz ; Fernandez-Hidalgo, Oscar ; Eslava, Marta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433u-b03274f7836628feee473d0b82a16af3b6be9746401c80816919940eed5703b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Breast cancer</topic><topic>Diagnosis</topic><topic>Hypothyroidism</topic><topic>Monoclonal antibodies</topic><topic>Risk factors</topic><topic>Targeted cancer therapy</topic><topic>Thyroid gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sánchez-Bayona, Rodrigo</creatorcontrib><creatorcontrib>Garcia del Barrio, Maria</creatorcontrib><creatorcontrib>Alegre, Estibaliz</creatorcontrib><creatorcontrib>Fernandez-Hidalgo, Oscar</creatorcontrib><creatorcontrib>Eslava, Marta</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Journal of cancer research and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sánchez-Bayona, Rodrigo</au><au>Garcia del Barrio, Maria</au><au>Alegre, Estibaliz</au><au>Fernandez-Hidalgo, Oscar</au><au>Eslava, Marta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trastuzumab and thyroid dysfunction: An association to be aware of</atitle><jtitle>Journal of cancer research and therapeutics</jtitle><date>2022-10-01</date><risdate>2022</risdate><volume>18</volume><issue>4</issue><spage>1183</spage><epage>1185</epage><pages>1183-1185</pages><issn>0973-1482</issn><eissn>1998-4138</eissn><abstract>The incidence of autoimmune thyroid disorders is higher among women with breast cancer (BC) than in other solid malignancies, while it has not a prognostic impact. Trastuzumab (T) is a humanized monoclonal antibody approved for human epidermal growth factor receptor 2 (HER2)-positive BC in the neoadjuvant, adjuvant, and metastatic scenarios. Since 2014, subcutaneous (SC) T has been employed with the same efficacy as the intravenous formulation together with an easier way of administration. To date, autoimmune thyroiditis has been linked rarely to the use of intravenous T, and no cases have been related to the SC presentation. We report two cases of HER2-positive early BC patients who developed hypothyroidism during maintenance therapy with SC T that required levothyroxine supplementation. SC T includes recombinant human hyaluronidase to facilitate tissue penetration of the drug. This enzyme may alter the thyroid gland stroma and facilitate the development of thyroid disorders. Thyroid function tests are recommended in patients on SC T.</abstract><cop>Mumbai</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><doi>10.4103/jcrt.JCRT_66_19</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0973-1482 |
| ispartof | Journal of cancer research and therapeutics, 2022-10, Vol.18 (4), p.1183-1185 |
| issn | 0973-1482 1998-4138 |
| language | eng |
| recordid | cdi_proquest_journals_2718075140 |
| source | Medknow Open Access Medical Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Breast cancer Diagnosis Hypothyroidism Monoclonal antibodies Risk factors Targeted cancer therapy Thyroid gland |
| title | Trastuzumab and thyroid dysfunction: An association to be aware of |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T12%3A54%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trastuzumab%20and%20thyroid%20dysfunction:%20An%20association%20to%20be%20aware%20of&rft.jtitle=Journal%20of%20cancer%20research%20and%20therapeutics&rft.au=S%C3%A1nchez-Bayona,%20Rodrigo&rft.date=2022-10-01&rft.volume=18&rft.issue=4&rft.spage=1183&rft.epage=1185&rft.pages=1183-1185&rft.issn=0973-1482&rft.eissn=1998-4138&rft_id=info:doi/10.4103/jcrt.JCRT_66_19&rft_dat=%3Cgale_proqu%3EA719770716%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2718075140&rft_id=info:pmid/&rft_galeid=A719770716&rfr_iscdi=true |